Experimental drug targets Hard-to-Treat leukemia in small early trial
NCT ID NCT07692529
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This early study tests an experimental drug called zeprumetostat in people with a rare type of leukemia (T-cell large granular lymphocyte leukemia) that has not responded to or has come back after other treatments. Ten participants take the drug twice daily for two 28-day cycles. The goal is to see if the drug can improve blood counts and reduce the need for transfusions, while also checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- zeprumetostat
- What this could lead to
- If it works, this could offer a new treatment option for people with a rare leukemia that has stopped responding to standard therapies.
- What could go wrong
- This is a very early, small study with only 10 participants. The drug may not work or could cause side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EVALUATION OF THE EFFICACY AND SAFETY OF ZEPRUMETOSTAT IN RELAPSED/REFRACTORY LARGE GRANULAR LYMPHOCYTE LEUKEMIA (T-LGLL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.